Pfizer Ltd. — Interim / Quarterly Report 2021

Nov 26, 2020

Limited

The Capital, 1802 / 1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

November 26, 2020

The Corporate Relationship Dept. BSE Limited 1[st] Floor, P.J.Towers Dalal Street, Fort Mumbai - 400 001 Scrip Code: 500680

The Manager, Listing Dept. The National Stock Exchange of India Ltd. Exchange Plaza, 5[th] Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’)

Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions, in the format specified in the accounting standards for the half year ended September 30, 2020.

The said disclosure is also available on the website of the Company i.e., www.pfizerindia.com

Please take the above on record.

Thanking you,

Yours truly,

For Pfizer Limited

==> picture [105 x 53] intentionally omitted <==

Prajeet Nair Company Secretary

Encl: A/a

==> picture [11 x 19] intentionally omitted <==

CIN: L24231MH1950PLC008311

contactus.india@pfizer.com www.pfizerindia.com

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2020

Currency: ₹ in crore

Related party transactions

• I. Names of related parties and description of relationships

• A. Parties where control exists:

• Ultimate holding company: Pfizer Inc., USA

B. Companies collectively exercising significant influence:

• Pfizer East India B.V., Netherlands Wyeth LLC, USA Wyeth Holdings Corporation, USA John Wyeth & Brother Limited, UK Warner - Lambert Company, LLC, USA Parke - Davis & Company, LLC, USA Pharmacia Corporation, USA [Collectively holding 63.92% of the aggregate of equity share capital of the Company]

C. Fellow subsidiaries with whom transactions have taken place during the half year/ year end

Pfizer Products India Private Limited, India Pfizer Innovative Supply Point International BVBA, Belgium Pfizer Service Company BVBA, Belgium Pfizer Worldwide Services, Ireland Pfizer Asia Manufacturing PTE, Singapore Pfizer Canada Inc

D. Key managerial personnel

Mr. S. Sridhar - Managing Director

Mr. Milind Patil - Wholetime Director & Chief Financial Officer

Mr. Vivek Dhariwal - Wholetime Director (upto 14 February 2020)

• Mr. Samir Kazi (w.e.f 14 February 2020)

Mr. R A Shah - Independent Director

• Mr. Pradip Shah - Independent Director

Mr. Uday Khanna - Independent Director

Mr. Sunil Lalbhai - Independent Director Ms.Meena Ganesh - Independent Director

E. Relative of Key managerial personnel

Mr. Akhilesh Iyer (upto 30 June 2020)

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2020

Currency: ₹ in crore

Transactions during the half year and balances outstanding as at the half year ended September 30, 2020 with the related parties are as follows:

	30 September 2020	30 September 2020	31 March 2020
	No. Nature of transactions Ultimate holding company Companies exercising significant influence Fellow subsidiaries Total		Ultimate holding company Companies exercising significant influence Fellow subsidiaries Total
	1 Service income - - 22.89 22.89 2 Recovery of expenses - - 0.12 0.12 3 Purchase of stock-in-trade - - 180.88 180.88 4 Purchase of raw / bulk materials - - 10.22 10.22 5 Dividend in respect of the year ended 31 March 2020/ 2019 - 965.02 - 965.02 6 Asset transfer - 2.12 2.12		- - 55.19 55.19 0.54 0.03 0.19 0.73 - - 393.41 393.41 - - 115.05 115.05 - 65.77 - 65.77 - 1.42 8.59 10.01
	30 September 2020		31 March 2020
	No. Nature of transactions Ultimate holding company Companies exercising significant influence Fellow subsidiaries Total		Ultimate holding company Companies exercising significant influence Fellow subsidiaries Total
	8 Outstanding as at the half year / year end – Due from - 0.09 9.52 9.61 9 Outstandingas at the halfyear /year end – Due to 11.05 6.46 138.43 155.94		0.54 0.09 20.9921.62 11.18 6.47 271.20 288.85
	Key managerial personnel No. Nature of transactions Half Year ended 30 September Year ended 31 March 2020
	No. Nature of transactions Half Year ended 30 September Year ended 31 March 2020
	1 Remuneration to keymanagementpersonnel 5.47* 9.22
	* Excludes amounts payable to key management personnel towards gratuity and compensated absences.
	Details of material transactions: Half Year ended 30 September Year ended 31 March 2020 a) Service income
	Half Year ended 30 September Year ended 31 March 2020
	a) Service income
	Pfizer Products India Private Limited 10.81 25.60 Pfizer Worldwide Services 12.09 29.59
	b) Recovery of expenses
	Pfizer Products India Private Limited 0.12 0.19
	Pfizer Inc., USA - 0.54 c) Purchase of stock in trade
	Pfizer Innovative Supply Point Intl BVBA, Belgium 17.25 66.07 Pfizer Service Company BVBA, Belgium 163.63 327.34 d) Purchase of raw/ bulk materials Pfizer Service Company BVBA, Belgium 6.79 111.62
	e) Dividend paid
	Pfizer East India B.V. 600.15 40.92 Wyeth LLC, USA 185.38 12.64
	g) Remuneration to key management personnel
	S. Sridhar 2.57 4.11 Milind Patil 1.61 2.10 Vivek Dhariwal (Upto 14 February 2020) - 1.88 Samir Kazi (w.e.f 14 February 2020) 0.88 0.16

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2020

Currency: ₹ in crore

Related party transactions (Continued)

	Related party transactions(Continued)
		Half Year ended 30 September 2020	As on 31 March 2020
	h) Outstanding as at the half year/ year end due from Pfizer Worldwide Services Pfizer Products India Private Limited, India	2.56 6.96 11.51 26.15 82.43	5.70 15.29
	i) Outstanding as at the half year/ year end due to
	Pfizer Innovative Supply Point Intl BVBA, Belgium Pfizer Service Company BVBA, Belgium Pfizer Export Company, Ireland		15.81 152.55 82.85